Comparative Pharmacology
Head-to-head clinical analysis: FURADANTIN versus MACRODANTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FURADANTIN versus MACRODANTIN.
FURADANTIN vs MACRODANTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit bacterial enzymes involved in cell wall synthesis, DNA replication, and RNA transcription. It is bactericidal against susceptible organisms.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit bacterial acetyl-CoA carboxylase, interfere with bacterial cell wall synthesis, and damage bacterial DNA. It is bactericidal against a broad spectrum of gram-positive and gram-negative bacteria.
100 mg orally twice daily for 5-7 days; acute uncomplicated cystitis: 50 mg four times daily or 100 mg twice daily for 5 days.
100 mg orally twice daily for 5 days; for uncomplicated UTI. Route: oral. Frequency: twice daily.
None Documented
None Documented
Terminal elimination half-life is 0.3-1 hour in adults with normal renal function; prolonged to 1-4 hours in renal impairment (creatinine clearance <60 mL/min) and may exceed 20 hours in anuria.
20-60 minutes (prolonged in renal impairment, up to 8 hours in anuria)
Renal: 36% (glomerular filtration and tubular secretion); fecal: 40-50% (biliary excretion and unabsorbed drug); hepatic metabolism: minor (acetylation and reduction) accounting for <10%.
Renal: 30-40% unchanged, Hepatic metabolism: 60-70% to inactive metabolites, Fecal: <1%
Category C
Category C
Urinary Anti-infective
Urinary Anti-infective